MRE11 Loss

CI-VAR-00002472Explore in graph →CIViC 370

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Endometrial Neoplasm1
MRE11 Loss	Talazoparib	Predictive	D	Supports Sensitivity Response	2	accepted	EID876 One endometrial cell line with decreased MRE11 expression caused by a homozygous poly(T) mutation exhibited increased sensitivity to the PARP inhibitor BMN-673. Loss of MRE11 was identified in 30.7% o… (full text at CIViC) PMID 24927325 · Koppensteiner et al., 2014 · Open in CIViC	civic
Malignant Prostate Neoplasm1
MRE11 Loss	Unspecified therapy	Predictive	C	Supports Sensitivity Response	2	rejected	EID877 One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11 gene and showed clinical response to PARP inhibitor olaparib. PMID 26510020 · Mateo et al., 2015 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.